Eli Lilly and Company (NYSE:LLY) Trading 2.3% Higher – What’s Next?

Shares of Eli Lilly and Company (NYSE:LLY) shot up 2.3% during trading on Thursday . The company traded as high as $1,047.30 and last traded at $1,041.8910. 2,699,576 shares traded hands during mid-day trading, a decline of 15% from the average session volume of 3,185,233 shares. The stock had previously closed at $1,018.87.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported standout Phase 3 obesity data for retatrutide, with weight loss results that appear stronger than many investors expected and that could expand the company’s already powerful GLP-1 franchise. Article: Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
• Positive Sentiment: The company said retatrutide produced clinically meaningful weight loss across doses, bringing it closer to a regulatory filing and a potential launch next year. Article: Patients on Lilly’s next-gen obesity drug lost 28% of body weight, company says
• Positive Sentiment: LLY also announced major oncology updates for the upcoming ASCO meeting, including plenary-session data for Retevmo and Verzenio, which supports confidence in the rest of Lilly’s pipeline beyond obesity. Article: Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
• Neutral Sentiment: Lilly completed a debt offering and acquired Engage Biologics for up to $202 million, moves that broaden its pipeline but are unlikely to be the main driver of the stock today. Article: Eli Lilly Raises $8.9 Billion in Debt Offering Article: Eli Lilly Buys Engage Biologics for Up to $202 Million
• Negative Sentiment: Lilly also disclosed a civil lawsuit alleging a Trulicity rebate-fraud scheme cost it more than $200 million, which adds a legal overhang even though it is not the main market-moving story. Article: Eli Lilly accuses church bishops, businessmen of fraud in Trulicity drug rebate scheme

Wall Street Analyst Weigh In

Several brokerages have commented on LLY. Daiwa Securities Group boosted their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. The Goldman Sachs Group boosted their target price on Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Barclays boosted their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. Wolfe Research reissued an “outperform” rating and set a $1,350.00 target price on shares of Eli Lilly and Company in a research note on Thursday. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,219.26.

Eli Lilly and Company Stock Performance

The company has a 50 day simple moving average of $940.69 and a 200 day simple moving average of $1,002.07. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock has a market cap of $981.19 billion, a price-to-earnings ratio of 37.01, a P/E/G ratio of 1.11 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the firm posted $3.34 earnings per share. The firm’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Essential Partners LLC boosted its holdings in Eli Lilly and Company by 32.0% in the first quarter. Essential Partners LLC now owns 293 shares of the company’s stock valued at $270,000 after acquiring an additional 71 shares during the last quarter. Vestor Capital LLC boosted its holdings in Eli Lilly and Company by 209.5% in the first quarter. Vestor Capital LLC now owns 10,787 shares of the company’s stock valued at $9,921,000 after acquiring an additional 7,302 shares during the last quarter. BankChampaign National Association bought a new stake in Eli Lilly and Company in the first quarter valued at approximately $1,031,000. Liontrust Investment Partners LLP boosted its holdings in Eli Lilly and Company by 46.7% in the first quarter. Liontrust Investment Partners LLP now owns 30,753 shares of the company’s stock valued at $28,286,000 after acquiring an additional 9,788 shares during the last quarter. Finally, Leigh Baldwin & CO. LLC boosted its holdings in Eli Lilly and Company by 2.3% in the first quarter. Leigh Baldwin & CO. LLC now owns 1,467 shares of the company’s stock valued at $1,349,000 after acquiring an additional 33 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.